CN108853071A - 用于联合治疗的药物组合物 - Google Patents

用于联合治疗的药物组合物 Download PDF

Info

Publication number
CN108853071A
CN108853071A CN201810580312.2A CN201810580312A CN108853071A CN 108853071 A CN108853071 A CN 108853071A CN 201810580312 A CN201810580312 A CN 201810580312A CN 108853071 A CN108853071 A CN 108853071A
Authority
CN
China
Prior art keywords
tesofensine
metoprolol
pharmaceutically acceptable
acceptable salt
obesity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201810580312.2A
Other languages
English (en)
Chinese (zh)
Inventor
亨里克·比约克·汉森
莫滕·格伦内特
博·约尔特·本特森
拉尔斯·伊韦莱德-尼尔森
约尔延·布斯·拉森
克劳斯·松德格伦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aniona APS
Original Assignee
Aniona APS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aniona APS filed Critical Aniona APS
Publication of CN108853071A publication Critical patent/CN108853071A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201810580312.2A 2012-02-16 2013-02-14 用于联合治疗的药物组合物 Pending CN108853071A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261599623P 2012-02-16 2012-02-16
DKPA201270076 2012-02-16
DKPA201270076 2012-02-16
US61/599,623 2012-02-16
CN201380020405.5A CN104244935A (zh) 2012-02-16 2013-02-14 用于联合治疗的药物组合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380020405.5A Division CN104244935A (zh) 2012-02-16 2013-02-14 用于联合治疗的药物组合物

Publications (1)

Publication Number Publication Date
CN108853071A true CN108853071A (zh) 2018-11-23

Family

ID=48983571

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201810580312.2A Pending CN108853071A (zh) 2012-02-16 2013-02-14 用于联合治疗的药物组合物
CN201810575583.9A Pending CN108434129A (zh) 2012-02-16 2013-02-14 用于联合治疗的药物组合物
CN201380020405.5A Pending CN104244935A (zh) 2012-02-16 2013-02-14 用于联合治疗的药物组合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201810575583.9A Pending CN108434129A (zh) 2012-02-16 2013-02-14 用于联合治疗的药物组合物
CN201380020405.5A Pending CN104244935A (zh) 2012-02-16 2013-02-14 用于联合治疗的药物组合物

Country Status (14)

Country Link
US (5) US9211271B2 (enExample)
EP (1) EP2814473B1 (enExample)
JP (1) JP6203760B2 (enExample)
CN (3) CN108853071A (enExample)
AU (1) AU2013220424B2 (enExample)
CA (1) CA2864264C (enExample)
DK (1) DK2814473T3 (enExample)
EA (1) EA029543B1 (enExample)
ES (1) ES2704987T3 (enExample)
HR (1) HRP20190050T1 (enExample)
LT (1) LT2814473T (enExample)
PL (1) PL2814473T3 (enExample)
SI (1) SI2814473T1 (enExample)
WO (1) WO2013120935A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108853071A (zh) * 2012-02-16 2018-11-23 萨尼奥纳有限责任公司 用于联合治疗的药物组合物
WO2015099796A1 (en) * 2013-12-28 2015-07-02 Intel Corporation System and method for device action and configuration based on user context detection from sensors in peripheral devices
CA2977415A1 (en) 2015-03-03 2016-09-09 Saniona A/S Tesofensine, beta blocker combination formulation
US20190060301A1 (en) 2016-01-15 2019-02-28 Saniona A/S Tesofensine and metoprolol for treatment of hypertension
RU2019109050A (ru) 2016-09-07 2020-10-08 Саниона А/С Композиции тезофензина
BR112021013463A2 (pt) 2019-01-07 2021-09-14 Saniona A/S Tesofensina para redução do peso corporal em pacientes com prader-willi
CN110297826B (zh) * 2019-05-31 2020-12-11 南京理工大学 基于json动态解析卫星遥测数据的方法
MX2022013236A (es) 2020-04-22 2023-01-24 Saniona As Tratamiento de la obesidad hipotalamica.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016197A1 (en) * 1991-03-18 1992-10-01 Sepracor Inc. Composition and method containing optically pure (s) metoprolol
WO2009080693A2 (en) * 2007-12-20 2009-07-02 Neurosearch A/S Pharmaceutical composition comprising tesofensine or its analogue and a beta blocker
WO2011100659A2 (en) * 2010-02-12 2011-08-18 Kitov Pharmaceutical Ltd. Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9707636A (pt) 1996-02-22 1999-07-27 Neurosearch As Composto composição farmacêutica uso de um composto e processos para preparar composto e para tratar um distúrbio ou doença de um organismo animal vivo
EP1727547A1 (en) 2004-01-22 2006-12-06 Neurosearch A/S Compounds for the sustained reduction of body weight
EP2222302A1 (en) 2007-11-20 2010-09-01 NeuroSearch A/S A method for treating over-eating disorders
US20100317572A1 (en) 2007-12-20 2010-12-16 Neurosearch A/S Pharmaceutical composition comprising tesofensine or its analogue and an anti-obesity compound
CN108853071A (zh) * 2012-02-16 2018-11-23 萨尼奥纳有限责任公司 用于联合治疗的药物组合物
CA2977415A1 (en) * 2015-03-03 2016-09-09 Saniona A/S Tesofensine, beta blocker combination formulation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016197A1 (en) * 1991-03-18 1992-10-01 Sepracor Inc. Composition and method containing optically pure (s) metoprolol
WO2009080693A2 (en) * 2007-12-20 2009-07-02 Neurosearch A/S Pharmaceutical composition comprising tesofensine or its analogue and a beta blocker
WO2011100659A2 (en) * 2010-02-12 2011-08-18 Kitov Pharmaceutical Ltd. Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ASTRUP A ET AL: ""Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial"", 《THE LANCET》 *

Also Published As

Publication number Publication date
PL2814473T3 (pl) 2019-06-28
SI2814473T1 (sl) 2019-03-29
CN108434129A (zh) 2018-08-24
EP2814473B1 (en) 2018-10-10
EP2814473A1 (en) 2014-12-24
DK2814473T3 (en) 2019-01-28
US20220016055A1 (en) 2022-01-20
WO2013120935A1 (en) 2013-08-22
CA2864264C (en) 2020-05-05
ES2704987T3 (es) 2019-03-21
US9211271B2 (en) 2015-12-15
US20160074344A1 (en) 2016-03-17
LT2814473T (lt) 2019-01-25
US20180185304A1 (en) 2018-07-05
JP2015508765A (ja) 2015-03-23
HK1204946A1 (en) 2015-12-11
AU2013220424A1 (en) 2014-09-25
US20170007557A1 (en) 2017-01-12
EA029543B1 (ru) 2018-04-30
CA2864264A1 (en) 2013-08-22
EA201491532A1 (ru) 2015-01-30
HRP20190050T1 (hr) 2019-03-08
AU2013220424B2 (en) 2017-03-23
US20150025107A1 (en) 2015-01-22
JP6203760B2 (ja) 2017-09-27
US9387184B2 (en) 2016-07-12
CN104244935A (zh) 2014-12-24

Similar Documents

Publication Publication Date Title
US20220016055A1 (en) Pharmaceutical Compositions For Combination Therapy
CA2683779C (en) Tapentadol for treating pain due to osteoarthritis
JP2016529307A (ja) アルツハイマー病の処置に使用するためのｈ３受容体アンタゴニスト
RU2007119067A (ru) Средство для лечения синдрома раздраженного кишечника с преобладанием диареи
JP2018515547A (ja) オピオイドとｎ−アシルエタノールアミンの組み合わせ
WO2005070427A1 (en) Compounds for the sustained reduction of body weight
US20130310412A1 (en) Combinations of an Opioid/TLR4 Antagonist and a Direct-Acting Alpha-2 Adrenergic Agonist for Use in the Treatment of Pain
US20140127302A1 (en) Analgesic Pharmaceutical Composition For Oral Administration
JP2012500248A (ja) 不安障害の治療
AU2012276476B2 (en) Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation
US20250302802A1 (en) Methods and compositions
JPWO2014034871A1 (ja) 脂質異常症の予防又は治療薬
CN102858339B (zh) 用于治疗疼痛的血清素和去甲肾上腺素再摄取抑制剂与类鸦片激动剂的组合
EP2588093B1 (en) Tapentadol for use in the treatment of irritable bowel syndrome
WO2009080693A2 (en) Pharmaceutical composition comprising tesofensine or its analogue and a beta blocker
HK40093852A (zh) 阿片类物质和n-酰基乙醇胺的组合
Keche et al. Comparison of the postoperative analgesia of intravenous infusion of adenosine and fentanyl
JP2008527034A5 (enExample)
US20120041014A1 (en) Methods of Converting a Patient's Treatment Regimen from Intravenous Administration of an Opioid to Oral Co-Administration of Morphine and Oxycodone Using a Dosing Algorithm to Provide Analgesia
JP2013537232A (ja) 鎮痛をもたらすために、オピオイドの静脈内投与から、投薬アルゴリズムを用いたモルヒネおよびオキシコドンの経口共投与へと、患者の処置レジメンを変換する方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20181123